http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2130460-C1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_cf32b60391b469c41e86c353437f5751 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02P20-55 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D498-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H19-01 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-06 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D498-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-357 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-436 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-352 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-407 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-445 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-40 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D498-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D498-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-435 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H19-01 |
| filingDate | 1994-05-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 1999-05-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b02188806e324c320269dd44f94cc0e5 |
| publicationDate | 1999-05-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2130460-C1 |
| titleOfInvention | Derivatives of tetrahydropyrane and pharmaceutical composition |
| abstract | FIELD: organic chemistry, pharmacy. SUBSTANCE: invention relates to new compounds of the formula (I) where R 1 means a group of the formula (1a) or (1b) where R 7 means optionally substituted hydroxy-group, acyloxy-group, halogen atom, -OR 10 where R 10 means lower alkyl optionally substituted with -O(CH 2 ) m OH where m is a number from 2 to 4 or -OCONH 2 ; R 7a means hydrogen atom; or R 7 and R 7a mean oxo-group; R 8 means hydroxy- or methoxy-group and R 9 means hydroxy- or acyloxy-group; R 2 means hydrogen atom, acyloxy- -group or optionally substituted hydroxy-group; between two carbon atoms bound with dotted line - a simple or double bond exists; R 3 means methyl, ethyl, n-propyl or allyl; or R 4 means hydrogen atom or hydroxy-group and R 4a means hydrogen atom; or R 4 and R 4a mean oxo-group; or R 5 means hydroxy-group and R 5a means hydrogen atom; or R 5 and R 5a/ mean oxo-group; A means a group of the formula -CH(OR 6 )-CH 2 -(CH 2 ) n or -CH= CH-(CH 2 ) n - bound with carbon atom through (CH 2 ) n -; R 6 means lower alkyl and n = 1 or 2. Compounds can be in free form or as salts. These compounds are used as pharmaceutical preparations, especially as anti-inflammatory and antiprofilerative agents. EFFECT: enhanced effectiveness of compounds as curative agents. 9 cl, 4 tbl, 36 ex |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2543721-C2 |
| priorityDate | 1993-05-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 73.